Jacqueline Rehn

Research Interests

Cancer Biology and Clinical Oncology Genomics and transcriptomics Bioinformatics Cancer Genetics

Dr Jacqueline Rehn

SAIGENCI

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Jacqueline Rehn is a Bioinformatician with the leukaemia research group at the South Australian Health and Medical Research Institute (SAHMRI). She completed her PhD in 2023 investigating bioinformatic methods for variant detection and subtype classification in acute lymphoblastic leukaemia (ALL). Her current research focuses on identifying novel disease drivers in ALL and understanding the impact of co-occurring mutations on disease.

Date Position Institution name
2025 - 2025 Affiliate Lecturer University of Adelaide
2018 - ongoing Bioinformatician South Australian Health and Medical Research Institute

Date Type Title Institution Name Country Amount
2024 Award New Directions in Leukaemia Research Poster Award NDLR Australia -
2024 Award Blood Travel Assistance Grant Haematology Society of Australia and New Zealand Australia -
2023 Award Minderoo Foundation Travel Grant Minderoo Foundation Australia -
2022 Award ZERO Symposium Virtual Poster Prize ZCC Australia -
2022 Scholarship Thomas William Hughes PhD Scholarship University of Adelaide Australia -
2022 Award New Directions in Leukaemia Research poster prize NDLR Australia -
2020 Award Adelaide Medical School Department of Medical Specialties Prize University of Adelaide Australia -
2020 Award John Barker Prize for Cancer Research University of Adelaide Australia -
2019 Scholarship Research Training Program Stipend University of Adelaide Australia -

Date Institution name Country Title
2023 University of Adelaide Australia PhD
2017 University of Adelaide Australia Masters of Biotechnology (Biomedical)
2006 Flinders University Australia Bachelor of Education (Secondary Science)

Year Citation
2025 Thomson, A., Rehn, J., Yeung, D., Breen, J., & White, D. (2025). Deciphering IGH rearrangement complexity and detection strategies in acute lymphoblastic leukaemia. npj Precision Oncology, 9(1), 99-1-99-11.
DOI Scopus1 WoS1 Europe PMC2
2025 Quinlan, L., Page, E. C., Rehn, J., McClure, B. J., Osborn, M. P., Moore, A. S., . . . Heatley, S. L. (2025). High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.. Pediatric Blood and Cancer, 72(11), e31983-1-e31983-7.
DOI
2024 Yeung, D. T., Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Page, E. C., . . . White, D. L. (2024). Diagnostic Genomic Analysis is Prognostic in AYA ALL Patients Treated on a MRD-Stratified Pediatric Protocol. Blood Neoplasia, 2(1), 100041.
DOI Scopus1
2023 Eadie, L. N., Rehn, J. A., Breen, J., Osborn, M. P., Jessop, S., Downes, C. E. J., . . . White, D. L. (2023). Case Report: Rare IKZF1 Gene Fusions Identified in Neonate with Congenital KMT2A-Rearranged Acute Lymphoblastic Leukemia. Genes, 14(2), 264-1-264-11.
DOI Scopus1 WoS1 Europe PMC1
2023 Page, E. C., Heatley, S. L., Rehn, J., Thomas, P. Q., Yeung, D. T., & White, D. L. (2023). Gain of chromosome 21 increases the propensity for P2RY8: :CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression. Frontiers in Oncology, 13(1177871), 1177871.
DOI Scopus8 WoS9 Europe PMC8
2023 Eadie, L. N., Rehn, J. A., Schutz, C. E., Heatley, S. L., Kutyna, M. M., Hiwase, D. K., . . . Yeung, D. T. (2023). Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling. British Journal of Haematology, 203(2), 282-287.
DOI Europe PMC1
2023 Thomson, A. J., Rehn, J. A., Heatley, S. L., Eadie, L. N., Page, E. C., Schutz, C., . . . White, D. L. (2023). Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients. Cancers, 15(19), 4731-1-4731-13.
DOI Scopus6 WoS6 Europe PMC6
2023 Nunn, J., Adayapalam, N., Riyat, S., Seymour, L., Williams, B., Rehn, J., . . . Tsuchiya, K. (2023). Paediatric B lymphoblastic leukaemia with hyperdiploidy and a false-positive KMT2A fluorescence in situ hybridization result. Cancer Genetics, 278-279, 80-83.
DOI Scopus2 WoS2 Europe PMC2
2022 Rehn, J., Mayoh, C., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C., . . . White, D. L. (2022). Rascall: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL). PLoS Genetics, 18(10), 1-23.
DOI Scopus18 WoS16 Europe PMC19
2022 Downes, C. E. J., Rehn, J., Heatley, S. L., Yeung, D., McClure, B. J., & White, D. L. (2022). Identification of a novel GOLGA4–JAK2 fusion gene in B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 196(3), 700-705.
DOI Scopus5 WoS5 Europe PMC5
2022 McClure, B. J., Pal, M., Heatley, S. L., Rehn, J., Schutz, C., Breen, J., . . . White, D. L. (2022). Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features. British Journal of Haematology, 196(6), 1407-1411.
DOI Scopus9 WoS8 Europe PMC7
2022 Kimura, S., Montefiori, L., Iacobucci, I., Zhao, Y., Gao, Q., Paietta, E. M., . . . Mullighan, C. G. (2022). Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood, 139(24), 3519-3531.
DOI Scopus40 WoS39 Europe PMC42
2022 Mäkinen, V. -P., Rehn, J., Breen, J., Yeung, D., & White, D. L. (2022). Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 23(9), 1-17.
DOI Scopus18 WoS14 Europe PMC23
2022 Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2022). Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis. Frontiers in Oncology, 12(851572), 851572-1-851572-6.
DOI Scopus3 WoS2 Europe PMC3
2021 Mallik, S., Yeung, D., Rehn, J., Nguyen, T., Dunlop, L., Kwan, J., & White, D. (2021). Monocytoid switch in an adult with B-cell precursor acute lymphoblastic leukaemia characterised by the PAX5 P80R mutation. Pathology, 54(5), 631-634.
DOI Scopus2 WoS2 Europe PMC1
2021 Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., . . . White, D. L. (2021). Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia. NPJ Precision Oncology, 5(1), 1-13.
DOI Scopus21 WoS20 Europe PMC17
2020 McClure, B. J., Heatley, S. L., Rehn, J., Breen, J., Sutton, R., Hughes, T. P., . . . White, D. L. (2020). High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. British Journal of Haematology, 191(2), 301-304.
DOI Scopus4 WoS3 Europe PMC3
2020 Rehn, J. A., O'Connor, M. J., White, D. L., & Yeung, D. T. (2020). DUX hunting-clinical features and diagnostic challenges associated with DUX4-rearranged leukaemia. Cancers (Basel), 12(10), 1-15.
DOI Scopus24 WoS23 Europe PMC27

Year Citation
2023 White, D. L., Rehn, J. A., Schutz, C. E., Heatley, S. L., Eadie, L. N., Thomson, A., . . . Greenwood, M. (2023). Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies. In BLOOD Vol. 142 (pp. 6 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI
2023 Eadie, L. N., Schutz, C. E., Page, E. C., Conlin, T. S., Heatley, S. L., Lagonik, E., . . . White, D. L. (2023). Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present. In BLOOD Vol. 142 (pp. 4 pages). CA, San Diego: AMER SOC HEMATOLOGY.
DOI WoS4
2021 Page, E. C., Heatley, S. L., Rehn, J., Yeung, D. T., Thomas, P. Q., & White, D. L. (2021). <i>HMGN1</i> expression Predisposes Down Syndrome Patients to Develop <i>P2RY8-CRLF2</i> acute Lymphoblastic Leukemia. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER.
DOI

Year Citation
2024 Rehn, J., Heatley, S., Page, E., Eadie, L., Schutz, C., Thomson, A., . . . White, D. (2024). Acquired copy number variants are highly correlated with Ph+ALL subgroups identified by transcriptomic analysis. Poster session presented at the meeting of Blood Annual Scientific Meeting.
2024 Rehn, J., Page, E., Heatley, S., Eadie, L., Schutz, C., Thomson, A., . . . White, D. (2024). Genomic characterisation of PAX5alt B-cell acute lymphoblastic leukaemia reveals novel PAX5 fusions. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting.
2023 Rehn, J., Schutz, C., Page, E., Heatley, S., Eadie, L., McClure, B., . . . White, D. (2023). High expression of DUX4 mRNA is a reliable indicator of DUX4-rearranged acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian and New Zealand Children’s Haematology/Oncology group (ANZCHOG) Scientific Meeting.
2022 Thomson, A., Rehn, J., Heatley, S., Eadie, L., McClure, B., Page, E., . . . White, D. (2022). Benchmarking the detection rate of IGH gene fusions in B-cell Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) Conference.
2021 Heatley, S. L., Page, E. C., Eadie, L. N., McClure, B. J., Rehn, J., Yeung, D. T., . . . White, D. L. (2021). Modeling Relapsed, Refractory Acute Lymphoblastic Leukemia from a Child with Neurofibromatosis. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS1
2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 4th International T-ALL/T-NHL conference: T-ALL2020: Omics, genetics and therapy.
2021 Eadie, L., Heatley, S., McClure, B., Rehn, J., Schutz, C., Breen, J., . . . White, D. (2021). Next Generation Genomic Analyses Inform Druggable Targets In T-All Patients. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
2021 Heatley, S., Rehn, J., Breen, J., Moore, A., Sutton, R., Osborn, M., & White, D. (2021). Using single cell mRNAseq to interrogate the genomic consequences of Ph-like acute lymphoblastic leukaemia in adolescents. Poster session presented at the meeting of 12th Biennial Childhood Leukemia and Lymphoma Symposium (CLLS).
2020 Eadie, L. N., Rehn, J., Heatley, S. L., McClure, B. J., Schutz, C. S., Breen, J., . . . White, D. L. (2020). Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER.
DOI WoS1
2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Targeted pseudo-alignment technique for rapid and accurate identification of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of 14th Annual Florey Postgraduate Conference. Adelaide, South Australia.
2020 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L. N., Schutz, C. E., . . . White, D. L. (2020). Pseudo-alignment technique for accurate detection of disease-causing variants in acute lymphoblastic leukaemia. Poster session presented at the meeting of Australian Bioinformatics and Computational Biology Society (ABACBS) 2020 National Conference. Canberra, ACT.
2020 Downes, C. E. J., McClure, B. J., Rehn, J., Breen, J., Bruning, J. B., Yeung, D. T., & White, D. L. (2020). Acquired Mutations within the JAK2 Kinase Domain Confer Resistance to JAK Inhibitors in an <i>in Vitro</i> model of a High-Risk Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. ELECTR NETWORK: ELSEVIER.
DOI WoS2
2019 Yeung, D., Greenwood, M., Rehn, J., Heatley, S., McClure, B., Eadie, L., . . . White, D. (2019). High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimen. Poster session presented at the meeting of Blood. Orlando, CA: American Society of Hematology.
DOI
2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of 1st European Society of Haematology (ESH) Translational Conference on ALL. Berlin, Germany.
2019 Eadie, L., Heatley, S. L., McClure, B. J., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploration of the Genomic Diversity in T-ALL Patients Using mRNA Sequencing. Poster session presented at the meeting of ASMR Annual Scientific Meeting. Adelaide, South Australia.
2019 Rehn, J. A., Breen, J., Heatley, S. L., McClure, B. J., Eadie, L., Schutz, C. E., . . . White, D. L. (2019). Investigating “alignment-free” computational techniques for the accurate identification of Acute Lymphoblastic Leukaemia (ALL) gene fusion events. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.
2019 Heatley, S. L., McClure, B. J., Eadie, L. N., Rehn, J. A., Breen, J., Hughes, T. P., . . . White, D. L. (2019). Exploring the genomic diversity of AYA and adult high-risk B-ALL cases by mRNA sequencing. Poster session presented at the meeting of SAHMRI Annual Scientific Meeting. Adelaide, South Australia.

Year Citation
- Rehn, J. (n.d.). RaScALL targets sequences.
DOI

Year Citation
2025 Eadie, L. N., McDougal, D. P., Lagonik, E., Schutz, C. E., Conlin, T. S., Page, E. C., . . . White, D. L. (2025). The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in
<i>ABL</i>
-rearranged ALL.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2024 Co-Supervisor Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events Doctor of Philosophy Doctorate Full Time Mrs Ashlee Jean Thomson-Roberts
2024 Co-Supervisor Clinical Transcriptomic Sequencing Analysis Workflows for Acute Lymphoblastic Leukaemia (ALL): Improving Subtype Characterisation in Complex Fusion Events Doctor of Philosophy Doctorate Full Time Mrs Ashlee Jean Thomson-Roberts

Date Role Committee Institution Country
2025 - ongoing Secretary EpiCSA Committee Epigenetics Consortium of South Australia Inc. Australia
2025 - ongoing Member ABACBS Postdoctoral Subcommittee Australian Bioinformatics and Computational Biology Society (ABACBS) Australia

Connect With Me

External Profiles

Other Links